



WE'LL EARN YOUR APPROVAL.

NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACT:

John Lehmann

440.801.1540

jlehmann@imarcresearch.com

Jim Tabaczynski

440.835.4525

jptgroup@sbcglobal.net

IMARC Signs Agreement with European CRO

TheraGenesis to help speed medical device approvals throughout Europe

CLEVELAND, Ohio — IMARC Research, a contract research organization based in Strongsville, Ohio, and TheraGenesis GmbH of Sutensee, Germany have signed a collaboration agreement to integrate and expand their combined resources, services and expertise in the development of medical devices. The agreement is solely a work-based collaboration with neither firm holding a financial stake in the other.

According to IMARC President Sandra Maddock, the collaboration expands IMARC's reach to include most European countries, helping to make it faster, easier and less costly for IMARC's U.S.-based clients to attain European approval. Maddock explained that joining forces with a company whose expertise lies within the regulatory and clinical framework of European countries increases IMARC's ability to better assist with trials running simultaneously in the U.S. and in Europe with Theragenesis and IMARC functioning as a single team covering all respective regions.

“We’ve had multiple opportunities to partner with other European CROs, but the cultures were never a fit,” said Ms. Maddock. “In the discussions I’ve had with TheraGenesis founder Erik Hesse, his commitment to quality and to exceeding customer expectations has come across loud and clear,” she continued. “I really believe that this exciting collaboration is a *win-win* for both IMARC and TheraGenesis as well as our clients.”

According to TheraGenesis' founder Erik Hesse, "Over the last 20 years, we have seen a strategic shift in the clinical and regulatory development of medical devices. Our industry demands speedy and consolidated international development. The collaboration of TheraGenesis and IMARC's operations and program-management structures will generate the developmental efficiencies to meet those demands on both sides of the Atlantic."

A privately-held, 15-year old company located in Strongsville, Ohio, IMARC assists the clinical research community in the pursuit of FDA and worldwide approvals. Our effectiveness is built on preparing, educating, complementing and guiding site teams from Day 1 — to control the complex management of trials via cost-effective monitoring, auditing and training services — which results in the support, proof and assurance they seek to overcome chaos caused by complexity while achieving compliance through consistency. Providing committed, competent and confident consultation is how IMARC sets the highest standards for site outcomes and study partnerships. Sites monitored from the start by IMARC have never received an FDA warning letter. More information is available at: www.imarcresearch.com

TheraGenesis GmbH is a contract research organization headquartered in Sutensee, Germany. Since it was established in 1995, TheraGenesis has extended its clinical trial management experience to virtually all European countries and virtually all areas of interventional medicine. The company's client base includes both blue-chip multinational medical device manufacturers, as well as venture capital and strategic-investment funded medical device entrepreneurs. TheraGenesis routinely provides authorized representative mandate services and has gained the confidence of the regulatory authorities and customers. More information is available at: www.theragenesis.com